Recently, the FDA Arthritis Advisory Committee reviewed the New Drug Application of the drug etoricoxib (Arcoxia), a COX-2 selective NSAID manufactured by Merck & Co., for use in the treatment of osteoarthritis pain. After review of available clinical data and testimony by invited experts and the manufacturer, the Committee voted 20 to 1 not to recommend approval of the drug to the FDA based on concerns regarding the cardiovascular risk profile of the drug. While not bound by the recommendations of the Committee, the FDA is expected to make further action recommendations in the next few weeks. Etoricoxib is currently licensed for use outside the U.S., including in Europe.
View the original article here
Return to Arthritis Knee Pain
![]() |
Incoming search terms:
- etoricoxib fda approval
- etoricoxib not working
Related posts:
- Duloxetine Fails To Get Indication Expansion For Chronic Pain An FDA panel opposed Eli Lilly’s efforts to broaden the...
- Arthritis Pain | Osteoarthritis Pain Life can be really miserable because of osteoarthritis pain. Matters...
- Arthritis | Know This: Arthritis Drugs Kill Posted By : Pmoyni Drug companies rolled out their latest lethal concoctions with warm...
- Osteoarthritis Treatment Recommendations That Work If you think you have osteoarthritis, you and your health...
- Is Glucosamine Sulfate an Effective Treatment for Osteoarthritis of the Hip? Radiograph showing advanced Osteoarthritis of the hip. Large scale, independent...
Tags: Advisory, Against, Approval, Arthritis, Etoricoxib, osteoarthritis, Panel, Votes

